Betaseron (Interferon Beta-1b) Patent Expiration, LOE Window & CMS Spending

Betaseron (Interferon Beta-1b) by Bayer: Biologic BLA (Purple Book Regime), 0 AB generics, $105.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayB103471 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$105.4M
2024 Medicare Part D Spend$92.2M
2024 Medicaid Spend$13.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 19.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.